Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pimavanserin adjunctive treatment for negative symptoms of schizophrenia
2016-003436-20Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Pimavanserin adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Change from baseline to Week 26 in Negative Symptom Assessment-16 total score. Started Feb 2017; status: completed.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-003436-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003436-20.